You can login if you already have an account or register by clicking the button below.
Registering is free and all you need is a username and password. We never ask you for your e-mail.
ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation.
I hope the trials will prove this drug to be effective. The current treatments are woefully inadequate.
view the rest of the comments →
[–] Allrightsreserved 0 points 1 point 1 point (+1|-0) ago
ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. I hope the trials will prove this drug to be effective. The current treatments are woefully inadequate.
[–] Imapopulistnow [S] 0 points 1 point 1 point (+1|-0) ago
faster, please...